Insider trade

Officer sold ~$2.06M of EXEL shares in the open market

Traded Nov 11, 2025 · Filed Nov 14, 2025

Why it stands out

Exelixis's Research and Development sold $2.06M of Exelixis shares. The filing references vesting of compensation awards.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,056,278

Shares × reported transaction price

Timing vs results

7 days after results of Nov 4, 2025, 62 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+2.1%	−1.9%	+4.0%
30 days	−0.7%	+1.3%	−2.0%
90 days	+2.5%	+1.4%	+1.1%
180 days	+23.1%	+10.5%	+12.7%

Past results only. Not a forecast.

Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $42.50 to $42.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.
Includes 431,306 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSU"). Each RSU is the economic equivalent of one share of Common Stock.